• careers
  • sitemap
  • contact

AdvaxisAdvaxis - Technology in Immunoterapy

  • Company
    • Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Why Listeria
    • How Advaxis Uses Listeria
    • Common Concerns
    • Intellectual Property
    • Bibliography
    • Vaccine Congress Presentation
  • Clinical Development
    • Lovaxin C
    • Lovaxin B
    • Lovaxin P
    • Lovaxin SCCE
  • Investors
    • Overview
    • Fact Sheet
    • Company PowerPoint
    • Webcasts
  • News
    • 2008 Press releases
    • 2007 Press releases
    • 2006 Press releases
    • 2005 Press releases
    • 2004 Press releases
    • 2003 Press releases
    • 2002 Press releases

Archives

  • 2008 Press Releases
  • 2007 Press Releases
  • 2006 Press Releases
  • 2005 Press Releases
  • 2004 Press Releases
  • 2003 Press Releases
  • 2002 Press Releases

News

2005 Press Releases

November 7, 2005
Advaxis, Inc and Cobra Biomanufacturing PLC enter a Strategic Collaboration and Long-Term Vaccine Supply Agreement for Listeria Cancer Vaccines

October 10, 2005
Advaxis’ vaccine candidate to treat existing cervical cancer

September 26, 2005
Advaxis’ Listeria Cancer vaccine results in complete regression of rapidly growing breast tumors

August 29, 2005
Advaxis’ Listeria Cancer Vaccine Shows Strong Safety Profile In Toxicology Studies

August 8, 2005
Advaxis, Inc. Release of Clinical GMP Materials for Phase I/II in Cervical cancer

July 28, 2005
Advaxis, Inc. Approved by NASD

January 12, 2005
Advaxis, Inc. Completes an additional US$1.1 Million Private Placement Financing

January 10, 2005
Great Expectations and Associates, Inc. Completes US$3,848,000 Private Placement Financing and changes its name to Advaxis, Inc

Home

Copyright © 2008 - Advaxis Inc. - All rights reserved